The three MM-derived cell lines RPMI8226, LP1, and OPM2, which were chosen due to the expression of both abnormal and normal MYC alleles, thereby capturing the diverse range of MYC expression patterns observed in MM patients (Table 1) [14,15], were transferred to SILAC medium 2 weeks before transduction with either non-target-control (NTC) sgRNA as control or MYC-targeting sgRNA(1) and sgRNA(2). This evidence concerns the gene MYC and Miyoshi myopathy.